Pre-made Trinbelimab benchmark antibody ( Whole mAb, anti-RhD/RHD therapeutic antibody, Anti-CD240D/DIIIc/HDFNRH/RH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhDCw/RhII/RhK562-II/RhPI Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Trinbelimab benchmark antibody (Whole mAb, anti-RhD/RHD therapeutic antibody, Anti-CD240D/DIIIc/HDFNRH/RH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhDCw/RhII/RhK562-II/RhPI Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Trinbelimab biosimilar, Whole mAb, Anti-RhD Antibody: Anti-CD240D/DIIIc/HDFNRH/RH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhDCw/RhII/RhK562-II/RhPI therapeutic antibody |
|---|---|
| INN Name | Trinbelimab |
| Target | RHD |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | Bharat Serums and Vaccines |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | RHD |
| Package |
